PA5-13725

antibody from Invitrogen Antibodies

Targeting: GRK1 GPRK1, RHOK, RK

Western blot (Data presented on provider website)

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-13725

Provider

Invitrogen Antibodies

Product name

GRK1 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Reactivity

Human, Mouse

Host

Rabbit

Isotype

IgG

Vial size

400 μL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles.

Tsujinaka H, Fu J, Shen J, Yu Y, Hafiz Z, Kays J, McKenzie D, Cardona D, Culp D, Peterson W, Gilger BC, Crean CS, Zhang JZ, Kanan Y, Yu W, Cleland JL, Yang M, Hanes J, Campochiaro PA
Nature communications 2020 Feb 4;11(1):694

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemistry analysis of GRK1 in formalin-fixed and paraffin-embedded human cancer tissue. Samples were incubated with GRK1 polyclonal antibody (Product # PA5-13725) which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemistry analysis of GRK1 in formalin-fixed and paraffin-embedded human hepatocarcinoma tissue. Samples were incubated with GRK1 polyclonal antibody (Product # PA5-13725) which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 5 Intravitreous injection of sunitinib MPs in mice with type 3 CNV reduces photoreceptor cell death. Rho/VEGF mice were given an intravitreous injection of 10 ug of sunitinib microparticles (Suni MP) in one eye and 10 ug of empty MP in the other eye or 40 ug of aflibercept in one eye and PBS in the fellow eye. At P42, mice ( n = 7 for each group) were euthanized and serial frozen ocular sections were cut from the superior pole of the eye (S0) to the inferior pole (I0) and sections 25% (S1 and I1), 50% (S2 and I2), and 75% (S3 and I3) of the distance between each pole and the optic nerve (ON) were stained with hematoxylin and outer nuclear layer (ONL) thickness was measured by image analysis by a masked investigator. The ONL of sections from the S2 location of Suni MP-injected eyes appeared thicker than those from empty MP-injected eyes, but those from aflibercept-injected eyes appeared similar to those from PBS-injected eyes ( a scale bar = 100 um). The mean (+-SEM) ONL thickness was significantly greater at three of six locations in Suni MP-injected eyes compared with empty MP-injected eyes, but there was no difference between aflibercept- and PBS-injected eyes ( b ). At P49, mice ( n = 5 for each group) were euthanized and immunoblots of retinal homogenates from Suni MP-injected eyes showed prominent bands for rhodopsin kinase (GRK-1) ( c ). Denistometry showed that the mean (+-SEM) GRK-1/Actin ratio was significantly greater in retinas from Suni MP-injected eyes compa